# Adam Stone

> Adam Stone is a Series B investor at Perceptive Advisors backing Biotechnology. See 8 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors)
- Location: New York, United States
- Total investments: 8
- Last investment: Jul 2026
- Lead investor: 75%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/adam-stone-0b0a551/

Adam Stone is a Series B investor at Perceptive Advisors in New York focused on Biotechnology and Therapeutics. Adam Stone is based out of New York, New York, and is the chief investment officer of Perceptive Advisors. Adam previously worked at Ursus Capital as a senior analyst. Adam Stone attended Princeton University.

## Contacts

5 contacts available for Adam Stone: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/adam-stone-5?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Therapeutics | 4 | 50% |
| Medical | 3 | 38% |
| Health Care | 3 | 38% |
| Health Diagnostics | 3 | 38% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 50% |
| Series A | 1 | 13% |
| Debt Financing | 1 | 13% |
| Private Equity | 1 | 13% |
| Post-IPO Equity | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $240M | Post-IPO Equity | Jul 20, 2026 | https://www.freenome.com/ |
| Lyte | Lyte is a technology platform that makes it easy for fans to buy, sell, and exchange tickets to live events. It also allows event owners to take control of their ticketing experience. Lyte was founded in 2013 and is headquartered in San Francisco, California. | $33M | Series B | Dec 17, 2020 | https://lyte.com/ |
| Prometheus Biosciences | Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenanceof clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rights to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California. | $130M | Private Equity | Nov 09, 2020 | https://www.prometheusbiosciences.com |
| C4 Therapeutics | C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causingproteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash.C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber. | $150M | Series B | Jun 16, 2020 | https://c4therapeutics.com |
| C4 Therapeutics | C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causingproteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash.C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber. | $20M | Debt Financing | Jun 16, 2020 | https://c4therapeutics.com |
| SpringWorks Therapeutics | SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others.The company was founded in 2017 and headquartered inConnecticut, United States. | $125M | Series B | Apr 01, 2019 | https://www.springworkstx.com/ |
| Partner Therapeutics | Partner Therapeutics is a developer of drugs for oncology treatment. The company focuses on the development and commercialization of approved and late-stage therapies that improve treatment outcomes and reduce the total cost of care for cancer. Its development spans the entire range of cancer therapy from primary treatments to supportive care. | $60M | Series A | Feb 01, 2018 | https://www.partnertx.com/ |
| Solid Biosciences | Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has anestimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial. | $42.5M | Series B | Nov 03, 2015 | http://solidbio.com/ |

8 of 8 investments shown.

## Co-investors
- [Adams Street Partners](https://shizune.co/investors/profile/adams-street-partners) — VC Fund, 2 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 2 deals together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 2 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 1 deal together

## About Perceptive Advisors

VC Fund · New York, United States

Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York,New York.

5 contacts available at Perceptive Advisors.

| Name | Title | Profile |
| --- | --- | --- |
| Ellen Hukkelhoven | Head of Investment Research | https://shizune.co/investors/profile/ellen-hukkelhoven |
| Fred Callori | Managing Director of Venture | https://shizune.co/investors/profile/fred-callori |
| Joseph Edelman | CEO & Founder | https://shizune.co/investors/profile/joseph-edelman |
| Orly Mishan | Managing Director, Perceptive Discovery | https://shizune.co/investors/profile/orly-mishan |
| Adam Stone | Chief Investment Officer | https://shizune.co/investors/profile/adam-stone-5 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Adam Stone invest in?

Adam Stone invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Adam Stone?

Public channels for Adam Stone include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Adam Stone last invest?

The most recent investment recorded for Adam Stone closed in Jul 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co